Welcome to our dedicated page for Nexentis Technologies SEC filings (Ticker: NITO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Nexentis Technologies's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Nexentis Technologies's regulatory disclosures and financial reporting.
Nexentis Technologies Inc. is asking stockholders at a Special Meeting on April 30, 2026 to approve four proposals: a reverse stock split (board authority to set a ratio between 1‑for‑2 and 1‑for‑500), stockholder approval to issue up to 20,000,000 shares (aggregate) in one or more non‑public offerings with aggregate consideration up to $100,000,000 and a maximum discount of 20%, and approval of an Amended and Restated Facility Agreement that increases available credit from €6,000,000 to €10,000,000 and adds a warrant price‑maintenance anti‑dilution mechanism which may reduce warrant exercise price or increase warrant shares. The Board unanimously recommends FOR all proposals; the record date is March 10, 2026.
Nexentis Technologies Inc. reported that on February 20, 2026, it issued 600,000 shares of common stock to consultants as payment for investor relations and business development services. The company treated this as a private, unregistered equity issuance relying on the Section 4(a)(2) exemption from the Securities Act.
N2OFF, Inc. is changing its corporate name to Nexentis Technologies Inc. and its Nasdaq trading symbol from NITO to NXTS, effective on the Nasdaq Capital Market on February 26, 2026. The change was approved by the board and implemented through a Nevada charter amendment that did not require shareholder approval.
The company states that the name and brand now reflect its evolution into an AI and data-driven computational biotech platform centered on mitochondrial biology, precision oncology and inflammatory metabolic diseases, built around its wholly owned subsidiary MitoCareX Bio Ltd. It will continue to manage its European RTB solar projects and majority stake in Save Foods Ltd. as part of a broader portfolio. The filing notes that existing stockholder rights and the common stock CUSIP number remain unchanged and that no stockholder action is required.
N2OFF, Inc. Amendment No. 1: Ciro Leonardo Pierri reports beneficial ownership of 227,064 common shares, representing 4.44% of the class based on 5,111,362 shares outstanding as of February 23, 2026. The filing states these shares are held directly by the reporting person.
Ciro Leonardo Pierri reported a passive ownership stake in N2OFF, Inc. He beneficially owns 227,064 shares of N2OFF common stock, representing 5.03% of the class, based on 4,511,362 shares outstanding as of February 12, 2026. Pierri has sole voting and dispositive power over all reported shares and certified that the holdings were not acquired to change or influence control of the company.
Zakai Shlomo reported acquisition or exercise transactions in a Form 4 filing for NITO. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 64,778 shares.
Barda Lital reported acquisition or exercise transactions in a Form 4 filing for NITO. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 64,370 shares.
Weiss Amitay reported acquisition or exercise transactions in this Form 4 filing.
N2OFF, Inc. reported that a trust associated with director Amitay Weiss was granted 116,286 restricted shares of common stock on February 9, 2026. The award was issued in accordance with the Save Foods, Inc. 2022 Share Incentive Plan and increased the trust’s indirect holdings to 129,144 shares.
N2OFF, Inc. reported an insider equity award for its Chief Executive Officer, David Palach. On February 9, 2026, a trust associated with him acquired 100,000 restricted shares of common stock at $0 per share under the Save Foods, Inc. 2022 Share Incentive Plan, bringing his indirectly held beneficial ownership to 129,144 shares.
N2OFF, Inc. has agreed to transfer all of its ordinary shares of its majority-owned subsidiary Save Foods Ltd., representing approximately 98% of Save Foods’ issued and outstanding share capital, to Voice Assist, Inc. under a Securities Exchange Agreement. In return, N2OFF will receive Voice Assist common stock equal to 19.99% of Voice Assist on a fully diluted basis, calculated immediately after closing. The closing is expected within 90 calendar days of the agreement, subject to customary conditions.
Separately, N2OFF entered a Services Agreement to provide non-exclusive advisory and support services to Voice Assist. As consideration, N2OFF is entitled to deferred cash of up to $1,000,000 funded from future Voice Assist financings over five years, royalties on gross profit from defined “New Future Projects” (75% for the first three years, 15% for years four through ten, and 5% thereafter), and 75% of any “Ecolab Gross Proceeds” tied to an “Ecolab Claim.” The equity issued in these transactions will rely on the Regulation S registration exemption.